Results: 6
Oral PCSK9 Inhibitors.
- Published in:
- Current Atherosclerosis Reports, 2024, v. 26, n. 5, p. 147, doi. 10.1007/s11883-024-01199-2
- By:
- Publication type:
- Article
Gene Editing for the Treatment of Hypercholesterolemia.
- Published in:
- Current Atherosclerosis Reports, 2024, v. 26, n. 5, p. 139, doi. 10.1007/s11883-024-01198-3
- By:
- Publication type:
- Article
Cardiovascular Effects of Stimulators of Soluble Guanylate Cyclase Administration: A Meta-analysis of Randomized Controlled Trials.
- Published in:
- Current Atherosclerosis Reports, 2024, v. 26, n. 5, p. 177, doi. 10.1007/s11883-024-01197-4
- By:
- Publication type:
- Article
The Effects of FABP4 on Cardiovascular Disease in the Aging Population.
- Published in:
- Current Atherosclerosis Reports, 2024, v. 26, n. 5, p. 163, doi. 10.1007/s11883-024-01196-5
- By:
- Publication type:
- Article
The Role of Genetics in Advancing Cardiometabolic Drug Development.
- Published in:
- Current Atherosclerosis Reports, 2024, v. 26, n. 5, p. 153, doi. 10.1007/s11883-024-01195-6
- By:
- Publication type:
- Article
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges.
- Published in:
- Current Atherosclerosis Reports, 2024, v. 26, n. 5, p. 133, doi. 10.1007/s11883-024-01194-7
- By:
- Publication type:
- Article